The business group MassBio has launched its annual temperature examine on the biotech business in Massachusetts, and the outcomes are grim.
Each private and non-private funding have plummeted as federal coverage modifications have thrown the biotech sector into an period of uncertainty. Enterprise capital funding in Massachusetts-based corporations dropped greater than 17% to $2.75 billion within the first half of 2025, in comparison with the identical interval in 2024, the bottom degree since 2017.
Massachusetts can also be projected to obtain round $463 million much less in Nationwide Institutes of Well being funding this 12 months than it did in 2024, based on MassBio, a commerce and lobbying group for the life sciences business.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.